KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Neogenomics (NEO) over the last 17 years, with Q3 2025 value amounting to $107.4 million.

  • Neogenomics' Cost of Revenue rose 1550.07% to $107.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $401.0 million, marking a year-over-year increase of 1024.73%. This contributed to the annual value of $370.5 million for FY2024, which is 675.05% up from last year.
  • Latest data reveals that Neogenomics reported Cost of Revenue of $107.4 million as of Q3 2025, which was up 1550.07% from $104.1 million recorded in Q2 2025.
  • In the past 5 years, Neogenomics' Cost of Revenue ranged from a high of $107.4 million in Q3 2025 and a low of $68.7 million during Q2 2021
  • Moreover, its 5-year median value for Cost of Revenue was $87.0 million (2023), whereas its average is $86.5 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first skyrocketed by 2396.54% in 2021, then soared by 174.59% in 2022.
  • Quarter analysis of 5 years shows Neogenomics' Cost of Revenue stood at $80.5 million in 2021, then rose by 1.75% to $81.9 million in 2022, then grew by 7.43% to $88.0 million in 2023, then increased by 7.71% to $94.7 million in 2024, then rose by 13.31% to $107.4 million in 2025.
  • Its Cost of Revenue was $107.4 million in Q3 2025, compared to $104.1 million in Q2 2025 and $94.8 million in Q1 2025.